期刊文献+

新生霉素衍生物FM-NOV17抑制Her2^+乳腺癌细胞的作用及其机制

Effects of FM-NOV17 on Her2^+ Breast Cancer Cells And its Mechanisim
暂未订购
导出
摘要 目的研究新生霉素衍生物FM-NOV17对乳腺癌Skbr3细胞的作用,并探讨该作用是否与其干扰热休克蛋白90(Hsp90)分子伴侣的功能从而促进Her2降解有关。方法用蛋白免疫印迹法检测Her2的含量,采用免疫共沉淀的方法研究FM-NOV17对乳腺癌细胞Hsp90分子伴侣功能的影响。用免疫共沉淀的方法将Her2与其分子伴侣复合物沉淀下来,用免疫印迹法检测沉淀物中与Her2结合的Hsp90和辅伴侣Hsp70含量的变化。结果 FM-NOV17能降低乳腺癌细胞Skbr3中Her2的蛋白水平,FM-NOV17使Her2与Hsp90和Hsp70的结合减少,降低Her2蛋白水平,诱导细胞周期阻滞和凋亡。结论 FM-NOV17通过干扰Hsp90伴侣功能,减少Her2与Hsp90和辅伴侣的结合,降低Her2蛋白量,最终抑制乳腺癌细胞增殖。 Objective To confirm the effects of FM-NOV17,one of novobiocin derivatives,on breast cancer cells(Skbr3),and to study the relationship between these effects and the molecular chaperone functions of heat shock protein 90(Hsp90). Methods The quantity of Her2 protein was determined by Western-blot. Molecular chaperone functions of Hsp90 on breast cancer cells were measured by coimmunoprecipitation. After the co-immunoprecipitation of Her2 and its molecular chaperones,the immunoprecipitate was then subjected to Western-blot analysis with anti-Her2 to study changes in quantity of antiHsp90,or anti-Hsp70 mAb. Results An exposure of Skbr3 cells to FM-NOV17 led to down-regulation of intracellular Her2 protein levels. FM-NOV17 treatment also decreased the binding of Her2 with Hsp90 and Hsp70. Consequently,apoptosis and cell cycle arrest were induced. Conclusions These studies demonstrate that the activities of FM-NOV17 might inhibit breast cancer cells through the disruption of Hsp90 chaperon function,which results in disruption of the binding of Her2 to Hsp90and cochaperons and the level of Her2 protein. That may be an important mechanism,by which FM-NOV17 mediates its effects on breast cancer cells.
出处 《福建医科大学学报》 北大核心 2015年第1期1-6,共6页 Journal of Fujian Medical University
基金 国家自然科学基金(81273541) 福建省自然科学基金杰出青年项目(2011J06013)
关键词 新生霉素 蛋白质类 Hsp90热休克蛋白质类 热休克蛋白质类 分子监控蛋白类 乳腺肿瘤/细胞学 novobiocin proteins Hsp90heat-shock proteins heat-shock proteins molecular chaperones breast neoplasms/cytology
  • 相关文献

参考文献14

  • 1Solit D B, Rosen N. Hsp90.- a novel target for cancer therapy [-J3. CurrTopMed Chem, 2006,6(11) :1205-1214.
  • 2Kr~mer O H, Mahboobi S, Sellmer A. Drugging the HDAC6- HSP90 interplay in malignant cells [J]. Trends Pharrnacol Sci, 2014,35(10) :501-509.
  • 3Choi J S, Kim H O, Kim E K, etal. HER2 expression in fine needle aspirates of lymph nodes detected by preoperative axil- lary ultrasound in breast cancer patients[J]. PloS One, 2014, 9(11) :e113065.
  • 4Proia D A, Bates R C. Ganetespib and HSP90: translatingpreclinical hypotheses into clinical promise[J]. Cancer Res, 2014,74(5) ~ 1294-1300.
  • 5Zagouri F, Sergentanis T N, Chrysikos D, etal. HspgO inhib- itors in breast cancer~ a systematic review[-J]. Breast, 2013, 22(5) :569-578.
  • 6Sidera K, Patsavoudi E. HSP90 inhibitors~ current develop- ment and potential in cancer therapy[J]. Recent Pat Antican- cer Drug Discov, 2014,9(1) :1-20.
  • 7Zhao J, Zhao H, Hall J A, et al. Triazole containing Novo- biocin and Biphenyl amides as Hspg0 C-Terminal inbibitors [J]. Medchemcomm, 2014,5(9) :1317-1323.
  • 8Audisio D, Methy-Gonnot D, Radanyi C, etal. Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors[J]. EurMed Chem, 2014,83:498-507.
  • 9Zhao H, Anyika M, Girgis A, et al. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines[J]. Bioorg Med Chem Lett, 2014, 24(15) ~3633-3637.
  • 10Wu LX, XuJ H, Zhang K Z, etal. Disruption of the Bcr- Abl/Hspg0 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocinrJ]. Leukemia, 2008,22(7) ..1402-1409.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部